Pharmaceutical Suspensions

1. Front Matter

   Pages i-xvi

   PDF

2. Various Pharmaceutical Disperse Systems

   • Chandrasekar Manoharan, Ashwin Basarkar, Jagdish Singh

   Pages 1-37

3. General Principles of Suspensions

   • Mohammad T. H. Nutan, Indra K. Reddy

   Pages 39-65

4. Commonly Used Excipients in Pharmaceutical Suspensions

   • R. Christian Moreton

   Pages 67-102

5. Pharmaceutical Development of Suspension Dosage Form

   • Yusuf Ali, Akio Kimura, Martin J. Coffey, Praveen Tyle

   Pages 103-126

6. Preclinical Development for Suspensions

   • Sudhakar Garad, Jianling Wang, Yatindra Joshi, Riccardo Panicucci

   Pages 127-176

7. Analytical Tools for Suspension Characterization

   • Alan F. Rawle

   Pages 177-230

8. Clinical Trials of Suspension Drug Products

   • G. Michael Wall, Terry K. Wiernas

   Pages 231-243

9. Scale Up and Technology Transfer of Pharmaceutical Suspensions

   • Yashwant Pathak, Deepak Thassu

   Pages 245-264

10. The Science and Regulatory Perspectives of Pharmaceutical Suspensions

    • Abhay Gupta, Vilayat A. Sayeed, Mansoor A. Khan

    Pages 265-283

11. Solid Nanosuspensions: The Emerging Technology and Pharmaceutical Applications as Nanomedicine

    • Sudhir Verma, Diane Burgess

    Pages 285-318

12. Back Matter

    Pages 319-327

    PDF

The suspension dosage form has long been used for poorly soluble active ingre- ents for various therapeutic indications. Development of stable suspensions over the shelf life of the drug product continues to be a challenge on many fronts. A good understanding of the fundamentals of disperse systems is essential in the development of a suitable pharmaceutical suspension. The development of a s- pension dosage form follows a very complicated path. The selection of the proper excipients (surfactants, viscosity imparting agents etc.) is important. The particle size distribution in the finished drug product dosage form is a critical parameter that significantly impacts the bioavailability and pharmacokinetics of the product. Appropriate analytical methodologies and instruments (chromatographs, visco- ters, particle size analyzers, etc.) must be utilized to properly characterize the s- pension formulation. The development process continues with a successful scale-up of the manufacturing process. Regulatory agencies around the world require cli- cal trials to establish the safety and efficacy of the drug product. All of this devel- ment work should culminate into a regulatory filing in accordance with the regulatory guidelines. Pharmaceutical Suspensions, From Formulation Development to Manufacturing, in its organization, follows the development approach used widely in the pharmaceutical industry. The primary focus of this book is on the classical disperse system – poorly soluble active pharmaceutical ingredients s- pended in a suitable vehicle.

• Formulation
• Kulshreshtha
• Singh
• Suspentions
• Wall
• clinical trial
• development
• drug
• kinetics
• manufacturing
• pharmaceutical
• pharmacokinetics
• research

• Alcon Research Ltd., Forth Worth, U.S.A.

  Alok K. Kulshreshtha, Onkar N. Singh, G. Michael Wall

ALOK K. KULSHRESHTHA, Ph.D., Associate Director, Pharmaceutical Technology at Alcon Research Ltd., Fort Worth, Texas, has 20 years of experience in the development of sterile ophthalmic, contact lens care, and dry eye products. During this tenure in pharmaceutical industry, Dr. Kulshreshtha has worked on several suspension drug products in different stages of development. Dr. Kulshreshtha’s interest in the suspension area started almost 30 years ago when he began his doctoral dissertation on  suspension rheology. Over the years, Dr. Kulshreshtha has worked on many new technologies for producing sterile suspensions. Dr. Kulshreshtha is the inventor/co-inventor of several Patents and has authored many peer reviewed publications. Dr. Kulshreshtha is a member of the American Association of Pharmaceutical Scientists (AAPS) and has been reviewer for AAPS abstracts screening for posters and symposia. Dr. Kulshreshtha holds a Ph.D. and M.S. in Chemical Engineering from Purdue University, and a Bachelor’s degree in Chemical Engineering from the Indian Institute of Technology, Kanpur, India.

ONKAR N. SINGH, Ph.D., M.B.A., Assistant Director, Development at Alcon Research Ltd., Fort Worth, Texas, has over 16 years of pharmaceutical product research and development of nasal, sterile ophthalmic, sterile otic, and parentral products. Dr. Singh is inventor/co-inventor of many patents related to formulations, process and formulation technology and has authored several peer reviewed articles. Prior to joining Alcon Inc., Dr. Singh was Manager at Access Pharmaceuticals, Dallas, Texas, leading efforts in the area of site specific targeted drug delivery systems for diagnostic and therapeutic areas of cancer therapy. At Access Pharmaceuticals, Dr. Singh worked on nanoparticles, liposomes, emulsion formulations, protein pharmaceuticals and gene delivery technology. Dr. Singh served as Secretary/Treasurer of the Ocular Focus Group of AAPS from 2002 to 2005 and has been a reviewer for AAPS abstracts, posters and symposia. Dr. Singh is a member of the American Association of Pharmaceutical Scientists (AAPS). Dr. Singh currently serves as an editorial board member of American Pharmaceutical Review Journal. Dr. Singh holds a B.S. in Pharmacy, M.S. in Pharmaceutics from Banaras Hindu University, India; Ph.D. in Pharmaceutics from University of Illinois at Chicago and M.B.A. from University of Texas at Arlington, Texas.

G. MICHAEL WALL, Ph.D., Senior Director of Pharmaceutical Products Development at Alcon Research, Ltd., Fort Worth, Texas, has over 21 years of pharmaceutical industrial experience in the development of intranasal, sterile ophthalmic and otic drug products. Dr. Wall is author or co-author of 2 patents and over 100 publications including peer-reviewed articles, abstracts, book chapters, book supplements and one book. Dr. Wall has led international, multidisciplinary teams in the development and approval of in the development and approval of Ciprodex® Sterile Otic Suspension and Patanase® Nasal Spray, as well as other products in countries around the world. Dr. Wall is a Scientific Fellow of the American Academy of Otolaryngology – Head and Neck Surgery. He has also served the American Chemical Society as a member for 30 years. Dr. Wall received a B.S. degree in chemistry from Auburn University, a M.S. degree in medicinal chemistry from Auburn University School of Pharmacy, a Ph.D. in medicinal chemistry from the University of Mississippi School of Pharmacy, and completed the Advanced Management Program (168^th session) of the Harvard Business School.

Policies and ethics